학술논문

Endocrine-Sensitive Disease Rate in Postmenopausal Patients with Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
Document Type
Article
Source
In: JAMA Oncology. (JAMA Oncology, 21 March 2024, 10(3):362-371)
Subject
Language
English
ISSN
23742445
23742437